Reuters logo
BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
October 24, 2017 / 9:55 PM / 2 months ago

BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA

Oct 24 (Reuters) - Clearside Biomedical Inc

* Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema

* Clearside Biomedical Inc - ‍patient follow-up in Tybee trial is 6 months​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below